Loading...
In a “Dear Healthcare Professional” letter dated February 6, 2012, the maker of the hepatitis C virus (HCV) protease inhibitor boceprevir warned providers that coadministering the drug with a ritonavir-boosted HIV protease inhibitor might reduce the effectiveness of both drugs. The warning is based on the results of a pharmacokinetic study in which concomitant administration of boceprevir with ritonavir-boosted darunavir, lopinavir/ritonavir, or ritonavir-boosted atazanavir led to reduced plasma concentrations of the HIV protease inhibitors. Furthermore, lopinavir/ritonavir and ritonavir-boosted darunavir substantially lowered boceprevir levels.
According to the letter, patients who are already taking boceprevir with a boosted HIV protease i…